Novo Nordisk’s site in Kalundborg, Denmark, already manufactures about half of the world’s insulin, but with a DKK 800 million makeover the site will be able to produce even more insulin and other products.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,